James D Phelan
Overview
Explore the profile of James D Phelan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
2572
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bolomsky A, Choi J, Phelan J
Methods Mol Biol
. 2024 Oct;
2865:241-257.
PMID: 39424727
Genome-wide screens are a powerful technique to dissect the complex network of genes regulating diverse cellular phenotypes. The recent adaptation of the CRISPR-Cas9 system for genome engineering has revolutionized functional...
2.
Nguyen H, Li M, Vadakath R, Henke K, Tran T, Li H, et al.
Nat Immunol
. 2024 Jul;
25(9):1718-1730.
PMID: 39025963
Germinal centers (GCs) that form in mucosal sites are exposed to gut-derived factors that have the potential to influence homeostasis independent of antigen receptor-driven selective processes. The G-protein Gα13 confines...
3.
Bolomsky A, Ceribelli M, Scheich S, Rinaldi K, Huang D, Chakraborty P, et al.
Cancer Cell
. 2024 Jun;
42(7):1185-1201.e14.
PMID: 38906156
Multiple myeloma (MM) is an incurable plasma cell malignancy that exploits transcriptional networks driven by IRF4. We employ a multi-omics approach to discover IRF4 vulnerabilities, integrating functional genomics screening, spatial...
4.
Melani C, Lakhotia R, Pittaluga S, Phelan J, Huang D, Wright G, et al.
N Engl J Med
. 2024 Jun;
390(23):2143-2155.
PMID: 38899693
Background: The identification of oncogenic mutations in diffuse large B-cell lymphoma (DLBCL) has led to the development of drugs that target essential survival pathways, but whether targeting multiple survival pathways...
5.
Choi J, Ceribelli M, Phelan J, Haupl B, Huang D, Wright G, et al.
Cancer Cell
. 2024 May;
42(5):833-849.e12.
PMID: 38701792
Glucocorticoids have been used for decades to treat lymphomas without an established mechanism of action. Using functional genomic, proteomic, and chemical screens, we discover that glucocorticoids inhibit oncogenic signaling by...
6.
Corcoran S, Phelan J, Choi J, Shevchenko G, Fenner R, Yu X, et al.
Cancer Discov
. 2024 Apr;
14(9):1653-1674.
PMID: 38683128
Polatuzumab vedotin (Pola-V) is an antibody-drug conjugate directed to the CD79B subunit of the B-cell receptor (BCR). When combined with conventional immunochemotherapy, Pola-V improves outcomes in diffuse large B-cell lymphoma...
7.
Roschewski M, Phelan J, Jaffe E
Blood
. 2024 Apr;
144(25):2593-2603.
PMID: 38635786
Diffuse large B-cell lymphoma (DLBCL) encompasses a diverse spectrum of aggressive B-cell lymphomas with remarkable genetic heterogeneity and myriad clinical presentations. Multiplatform genomic analyses of DLBCL have identified oncogenic drivers...
8.
Radtke A, Postovalova E, Varlamova A, Bagaev A, Sorokina M, Kudryashova O, et al.
Cancer Cell
. 2024 Mar;
42(3):444-463.e10.
PMID: 38428410
Follicular lymphoma (FL) is a generally incurable malignancy that evolves from developmentally blocked germinal center (GC) B cells. To promote survival and immune escape, tumor B cells undergo significant genetic...
9.
Phelan J, Scheich S, Choi J, Wright G, Haupl B, Young R, et al.
Cancer Cell
. 2024 Jan;
42(2):238-252.e9.
PMID: 38215749
Diffuse large B cell lymphoma (DLBCL) is an aggressive, profoundly heterogeneous cancer, presenting a challenge for precision medicine. Bruton's tyrosine kinase (BTK) inhibitors block B cell receptor (BCR) signaling and...
10.